Epistaxis complicated by rivaroxaban managed with topical tranexamic acid

Published:March 06, 2015DOI:
      The use of topical tranexamic acid has been evaluated in the literature for the management of epistaxis, both uncomplicated and secondary to coagulation disorders. Although it has been proposed to have a role in the treatment of bleeding secondary to target specific oral anticoagulants, there is minimal experience described in the literature related to its utility in the clinical setting. We present the first known case report of epistaxis complicated by outpatient rivaroxaban therapy in an elderly patient that was managed with topical tranexamic acid.
      To read this article in full you will need to make a payment
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to The American Journal of Emergency Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Tibbelin A.
        • Aust R.
        • Bende M.
        • Holgersson M.
        • Petruson B.
        • Rundcrantz H.
        • et al.
        Effect of local tranexamic acid gel in the treatment of epistaxis.
        ORL J Otorhinolaryngol Relat Spec. 1995; 57: 207-209
        • Zahed R.
        • Moharamzadeh P.
        • Alizadeharasi S.
        • Ghasemi A.
        • Saeedi M.
        A new and rapid method for epistaxis treatment using injectable form of tranexamic acid topically: a randomized controlled trial.
        Am J Emerg Med. 2013; 31: 1389-1392
        • Thorsen S.
        Differences in the binding to fibrin of native plasminogen and plasminogen modified by proteolytic degradation. Influence of omega-aminocarboxylic acids.
        Biochim Biophys Acta. 1975; 393: 55-65
        • Hoylaerts M.
        • Lijnen H.R.
        • Collen D.S.
        Studies on the mechanism of the antifibrinolytic action of tranexamic acid.
        Biochim Biophys Acta. 1981; 673: 75-85
        • Kubitza D.
        • Becka M.
        • Mueck W.
        • Halabi A.
        • Maatouk H.
        • Klause N.
        • et al.
        Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct factor Xa inhibitor.
        Br J Clin Pharmacol. 2010; 70: 703-712
        • Kubitza D.
        • Becka M.
        • Roth A.
        • Mueck W.
        The influence of age and gender on the pharmacokinetics and pharmacodynamics of rivaroxaban—an oral, direct factor Xa inhibitor.
        J Clin Pharmacol. 2013; 53: 249-255
        • Kubitza D.
        • Becka M.
        • Mueck W.
        • Zuehlsdorf M.
        The effect of extreme age and gender on the pharmacology and tolerability of rivaroxaban, an oral direct Xa inhibitor.
        Blood. 2006; 108 ([Abstract 905])
        • Gruenebaum D.D.
        • Alsarah A.
        • Alsara O.
        • Laird-Fick H.
        Bleeding complication of triple therapy of rivaroxaban, prasugrel, and aspirin: a case report and general discussion.
        Case Rep Cardiol. 2014; 2014: 293476
      1. Xarelto [package insert].
        Jansen Pharmaceuticals, Titusville, NJ2015
        • Samama M.M.
        • Contant G.
        • Spiro T.E.
        • Perzborn E.
        • Le Flem L.
        • Guinet C.
        • et al.
        Laboratory assessment of rivaroxaban: a review.
        Thromb J. 2013; 11: 11
        • Samama M.M.
        • Martinoli J.L.
        • Leflem L.
        • Guinet C.
        • Plu-Bureau G.
        • Depasse F.
        • et al.
        Assessment of laboratory assays to measure rivaroxaban—an oral, direct factor Xa inhibitor.
        Thromb Haemost. 2010; 103: 815-825
        • Hillarp A.
        • Baghaei F.
        • Fagerberg Blixter I.
        • Gustafsson K.M.
        • Stigendal L.
        • Sten-Linder M.
        • et al.
        Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays.
        J Thromb Haemost. 2011; 9: 133-139
        • Mani H.
        • Hesse C.
        • Stratmann G.
        • Lindhoff-Last E.
        Rivaroxaban differentially influences ex vivo global coagulation assays based on the administration time.
        Thromb Haemost. 2011; 106: 156-164
        • van Veen J.J.
        • Smith J.
        • Kitchen S.
        • Makris M.
        Normal prothrombin time in the presence of therapeutic levels of rivaroxaban.
        Br J Haematol. 2013; 160: 859-861
        • Heidbuchel H.
        • Verhamme P.
        • Alings M.
        • Antz M.
        • Hacke W.
        • Oldgren J.
        • et al.
        European Heart Rhythm Association practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation.
        Europace. 2013; 15: 625-651
        • Brem E.
        • Koyfman A.
        • Foran M.
        Review of recently approved alternatives to anticoagulation with warfarin for emergency clinicians.
        J Emerg Med. 2013; 45: 143-149
        • Yen S.H.
        • Lin P.C.
        • Kuo F.C.
        • Wang J.W.
        Thromboprophylaxis after minimally invasive total knee arthroplasty: a comparison of rivaroxaban and enoxaparin.
        Biomed J. 2014; 37: 199-204
        • Clavé A.
        • Fazilleau F.
        • Dumser D.
        • Lacroix J.
        Efficacy of tranexamic acid on blood loss after primary cementless total hip replacement with rivaroxaban thromboprophylaxis: a case-control study in 70 patients.
        Orthop Traumatol Surg Res. 2012; 98: 484-490